89 related articles for article (PubMed ID: 17068880)
1. [Unusual, unilateral metastasis of a prostate-carcinoma and palliative rhenium-186 pain-therapy].
Breidert-Backes I; Adams S; Baum RP; Hör G
Nuklearmedizin; 1997 Dec; 36(8):289-91. PubMed ID: 17068880
[TBL] [Abstract][Full Text] [Related]
2. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
Limouris G; Shukla SK; Manetou A; Kouvaris I; Plataniotis G; Triantafyllou N; Rigas AV; Vlahos L
Anticancer Res; 1997; 17(3B):1699-704. PubMed ID: 9179222
[TBL] [Abstract][Full Text] [Related]
3. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
4. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Klutmann S; Bohuslavizki KH
MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
[TBL] [Abstract][Full Text] [Related]
5. [Advanced prostate carcinoma: systemic radionuclide therapy of bone metastasis with rhenium-168-hydroxyethylidine diphosphonate].
Lerch H
Strahlenther Onkol; 1998 Jul; 174(7):384-5. PubMed ID: 9689963
[No Abstract] [Full Text] [Related]
6. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
[TBL] [Abstract][Full Text] [Related]
7. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
Hauswirth AE; Palmedo H; Dierke-Dzierzon C; Biersack HJ; Krebs D
Zentralbl Gynakol; 1998; 120(2):83-6. PubMed ID: 9531713
[TBL] [Abstract][Full Text] [Related]
8. Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma.
Tennvall J; Abrahamsson PA; Ahlgren G; Darte L; Flodgren P; Garkavij M; Strand SE
Scand J Urol Nephrol; 2000 Jun; 34(3):188-93. PubMed ID: 10961473
[TBL] [Abstract][Full Text] [Related]
9. [Pain palliation using unsealed radionuclides].
Kampen WU; Fischer M
Schmerz; 2008 Dec; 22(6):699-705; quiz 706. PubMed ID: 18846393
[TBL] [Abstract][Full Text] [Related]
10. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
11. [Bone scintigraphy and rhenium radioisotope management in the course of metastatic prostatic cancer].
Ostwald E; Sabri O; Cremerius U; Jakse G; Büll U
Nuklearmedizin; 1999; 38(7):302-5. PubMed ID: 10599071
[TBL] [Abstract][Full Text] [Related]
12. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma.
De Winter F; Brans B; Van De Wiele C; Dierckx RA
Clin Nucl Med; 1999 Nov; 24(11):898-9. PubMed ID: 10551482
[No Abstract] [Full Text] [Related]
13. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
Quirijnen JM; Han SH; Zonnenberg BA; de Klerk JM; van het Schip AD; van Dijk A; ten Kroode HF; Blijham GH; van Rijk PP
J Nucl Med; 1996 Sep; 37(9):1511-5. PubMed ID: 8790203
[TBL] [Abstract][Full Text] [Related]
15. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
Silberstein EB
J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054
[No Abstract] [Full Text] [Related]
16. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
Rubini G; Nicoletti A; Rubini D; Asabella AN
Cancer Biother Radiopharm; 2014 Feb; 29(1):1-11. PubMed ID: 24180669
[TBL] [Abstract][Full Text] [Related]
17. Rhenium-188-HEDP in the palliative treatment of bone metastases.
Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG
Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
19. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
20. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]